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Abstract.
Background: Collection of cerebrospinal fluid (CSF) for measurement of amyloid- (A) species is a gold standard in
Alzheimer’s disease (AD) diagnosis, but has risks. Thus, establishing a low-risk blood A test with high AD sensitivity and
specificity is of outmost interest.
Objective: We evaluated the ability of a commercially available plasma A assay to distinguish AD patients from biomarker-
healthy controls.
Method: In a case-control design, we examined plasma samples from 44 AD patients (A + N+) and 49 controls (A–N–) from
a memory clinic. AD was diagnosed using a combination of neuropsychological examination, CSF biomarker analysis and
brain imaging. Total A40 and total A42 in plasma were measured through enzyme-linked immunosorbent assay (ELISA)
technology using ABtest40 and ABtest42 test kits (Araclon Biotech Ltd.). Receiver operating characteristic (ROC) analyses
with outcome AD were performed, and sensitivity and specificity were calculated.
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Results:Plasma A42/40 was weakly positively correlated with CSF A42/40 (Spearman’s rho 0.22; p = 0.037). Plasma A42/40
alone was not able to statistically significantly distinguish between AD patients and controls (AUC 0.58; 95% CI 0.46, 0.70).
At a cut-point of 0.076 maximizing sensitivity and specificity, plasma A42/40 had a sensitivity of 61.2% and a specificity of
63.6%.
Conclusion: In this sample, the high-throughput blood A assay was not able to distinguish well between AD patients and
controls. Whether or not the assay may be useful in large-scale epidemiological settings remains to be seen.
Keywords: Alzheimer’s disease, amyloid, diagnosis, high-throughput assay, plasma
INTRODUCTION
Alzheimer’s disease (AD) is threatening global
healthcare systems [1] and generates immense eco-
nomic, medical, and societal costs [2]. As its
neuropathological hallmark, AD is characterized by
an accumulation of amyloid- (A) peptides in the
brain and AD diagnosis largely depends on an esti-
mation of brain A burden. A is derived through
cleavage of the amyloid- protein precursor (APP),
a transmembrane protein, and aggregates as neuro-
toxic amyloid plaques ultimately impairing synaptic
function [3], though whether or not A causes AD or
functions as a ‘bystander’ of AD pathogenesis is yet
to be determined [4, 5].
Brain A antemortem is quantifiable via radio-
active labelling on positron emission tomography
(PET) [6] and can also be estimated from A concen-
trations in cerebrospinal fluid (CSF) as a molecular
biomarker [7]. Amyloid PET and CSF A can be
used interchangeably for clinical diagnosis [7, 8] and
are increasingly relied upon in diagnostic frameworks
[9, 10]. Both have also been shown to predict future
cognitive decline [11–13]. Nonetheless, amyloid PET
and CSF A are used infrequently in clinical practice
[14]. Amyloid PET is cost-intensive and dependent
on radioactive tracers; lumbar punctures to obtain
CSF can cause minor complications such as back
pain as well as more severe complications such as
spinal hematoma [15], and can lead to psycholog-
ical distress [16]. In contrast, blood collection is
well-tolerated, making measurement of blood A for
estimation of brain A burden suitable for large-scale
application in routine diagnostics. For instance, with
sufficient sensitivity and specificity, analysis of blood
A could serve as a first-step screening tool for selec-
tion of patients for more cost-intensive and high-risk
diagnostic measures. Ultimately, blood A analysis
might have a comparable impact on diagnostic pro-
cedures as amyloid PET [6, 17] and CSF A analysis
[18, 19], and even more so due to a projected wider
uptake.
However, measuring A in blood is inherently
difficult [20, 21]. Plasma concentrations of A are
around 10-fold lower than in CSF, whereas the
total protein content is 10-fold higher [22], causing
technical difficulties. Sophisticated methods for A
analysis have been developed in recent years, but
results from the first diagnostic and epidemiological
applications of these methods have been inconsistent.
A number of studies have found an association of
lower plasma A concentrations (thought to reflect
a greater brain A burden) with more severe neu-
ropsychological deficits [23, 24], with an increased
risk of developing AD [25, 26], and with amyloid-
positive PET [8, 27, 28] or amyloid-abnormal CSF
[29, 30] as current gold standards for AD diagno-
sis. Others report results in the opposite direction
[31–34] and null findings, too, are frequent [35–37].
It has been suggested that one reason for this incon-
sistency may lie in between-study differences in the
cognitive profiles of study samples given that plasma
A levels follow a complex temporal trajectory: con-
centrations increase with age but, potentially due to
brain A aggregation, reduce in symptomatic stages
of AD [22, 32, 38]. The inconsistent research find-
ings may additionally stem from variations in A
measurement methods. Of note, in-house methods
with limited feasibility for upscaling are frequent [27]
but hinder clinical application which is dependent on
high-throughput methods.
Here, we determined the ability of plasma A
concentration to discriminate between AD patients
and biomarker-healthy, non-diseased controls. We
used a recently established, commercially available
and high-throughput plasma A assay that to our
knowledge has never been evaluated independently
of the manufacturer. We hypothesized that A con-
centration was lower in the plasma of AD patients
than in controls. The ratio of plasma A42/40 served
as the main biomarker of interest as it reflects the
more pathological of the amyloid species (A42) [39]
with individual differences in overall A production
(A40) accounted for.
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MATERIALS AND METHOD
Study design and sample size calculation
In a case-control study design, A was measured
in plasma samples previously stored at a biobank
for AD patients and biomarker-healthy, non-diseased
controls. With a two-tailed analysis and a power of
80%, 47 observations were required per group (total
N = 94) to detect statistically significant group differ-
ences in plasma A (expected effect size d = 0.6).
To account for occasional technical difficulty in
biomarker measurement, we arrived at a target sam-
ple size of N = 100. The study complied with the
Declaration of Helsinki.
Study sample
Cases in our study included patients with AD, who
were diagnosed during a visit to a memory clinic in
Berlin, Germany, between 2014 and 2018. Controls
were selected among individuals who presented to the
clinic with memory concerns during the same time
period, but who were otherwise neurobiologically
healthy and consequently did not receive a diagno-
sis of AD or other forms of dementia. The memory
clinic is part of the German Dementia Competence
Network (DCN). AD patients and controls were not
matched.
Clinical examinations
All participants underwent a thorough and iden-
tical clinical examination that included lumbar
puncture for CSF collection and collection of blood.
Participants were not required to fast. Plasma sam-
ples were stored at a biobank for future analysis. CSF
was collected into polypropylene tubes and frozen at
–80◦C according to standard operating procedures
detailed elsewhere [40]. Total tau (t-tau), A40, and
A42 in CSF were measured in Mesoscale Sys-
tem (MSD) immunoassays (Mesoscale Discovery,
Gaithersburg, MD, USA) at a laboratory adjacent to
the clinic site. For t-tau, the MSD MS6000 Phospho-
, Total Tau Kit was used; for A40 and A42, the
MSD MS6000 Human (6E10) A3-Plex Kit was
used [41]. The ratio A42/40 was calculated. Consent-
ing participants were genotyped for apolipoprotein
(APOE) status. ‘APOE 4’ was defined as presence
of at least one 4 allele. Participants addition-
ally underwent computed tomography (CT) and/or
magnetic resonance imaging (MRI) on a separate
visit. Neuropsychological testing was mainly based
on the CERAD (Consortium to Establish a Reg-
istry for Alzheimer’s Disease) recommendations.
Tests included the Mini-Mental State Examination
(MMSE) [42], Boston Naming, verbal fluency (cate-
gory), figure copying, and word list recall. The battery
was supplemented by the Clock Drawing test as a
screening tool for dementia and Trail-Making Tests
A and B (TMT-A; TMT-B) as measures of processing
speed and executive function. The Logical Memory
subtest of the Wechsler Memory Scale 4th edition
assessed verbal memory and included immediate and
delayed recall.
Clinical diagnosis of cases and controls
AD was diagnosed according to DSM-V criteria
in a consensus conference involving psychiatrists,
physicians and neuropsychologists from a com-
bination of results from the neuropsychological
examination, CSF biomarker analysis and brain
imaging data. Diagnostic confidence was exception-
ally high compared with non-specialized centers, as
AD patients were selected for enrollment into clin-
ical trials at the memory clinic. AD patients were
thus considered both clinically and neurobiologically
diseased, whereas the control group was considered
biomarker-healthy. Plasma A concentration was
unknown at the time of diagnosis.
Aβ in plasma
Plasma samples were extracted from the biobank
in 2018 and shipped to an analysis laboratory (Ara-
clon Biotech Ltd., Zaragoza, Spain) for measurement
of total A40 (referred to as A40 hereafter) and
total A42 (referred to as A42 hereafter) through
enzyme-linked immunosorbent assay (ELISA) tech-
nology using the ABtest40 and ABtest42 test kits
(Araclon Biotech Ltd., Zaragoza, Spain) [43]. The
laboratory was blinded to our research question and to
patient characteristics. Of N = 100, the analysis pro-
duced data on A40 for n = 97 (n = 50 controls; n = 47
patients) and on A42 for n = 93 participants (n = 49
controls; n = 44 patients). Intra-assay coefficient of
variation (CV) was 4.5% for A40 and 15.8% for
A42. Inter-assay CV was 3.7% for A40 and 5.0%
for A42. The ratio A42/40 was calculated for n = 49
controls and n = 44 patients, and served as the main
plasma biomarker of interest.
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Table 1
Sociodemographic, clinical, and cognitive characteristics in controls and AD patients
Controls (n = 50) AD (n = 50) p
Age, years, mean ± SD 65.82 ± 8.96 71.30 ± 7.42 0.001
Female sex, n (%) 26 (52.0%) 25 (50.0%) 0.841
Years of education*, mean ± SD 14.27 ± 2.98 13.46 ± 2.96 0.187
≥1 APOE 4 allele**, n (%) 11 (26.8%) 33 (71.7%) <0.001
Results from t-tests, Mann-Whitney tests or χ2 tests. *total n = 94. **total n = 87.
Table 2
Correlations of plasma A with CSF A
CSF A40 CSF A42 CSF A42/40
Total sample
Plasma A40 0.10 (0.350) –0.05 (0.637) –0.14 (0.171)
Plasma A42 0.24 (0.023) 0.26 (0.012) 0.13 (0.220)
Plasma A42/40 0.23 (0.029) 0.33 (0.001) 0.22 (0.037)
Controls
Plasma A40 –0.05 (0.741) –0.07 (0.636) –0.11 (0.482)
Plasma A42 0.15 (0.332) 0.31 (0.043) 0.24 (0.112)
Plasma A42/40 0.15 (0.334) 0.34 (0.026) 0.29 (0.052)
AD
Plasma A40 0.22 (0.131) –0.01 (0.953) –0.32 (0.025)
Plasma A42 0.27 (0.057) 0.23 (0.116) –0.04 (0.761)
Plasma A42/40 0.26 (0.071) 0.28 (0.053) 0.07 (0.636)
Spearman’s rho (p-value). CSF; cerebrospinal fluid. n = 44 to 97.
Statistical analysis
Differences between AD patients and controls in
terms of sociodemographics, frequency of the APOE
4 allele and CSF biomarkers were compared using
independent samples t-tests, Mann-Whitney tests or
χ2 tests. In the total sample, associations of plasma
A42, A40, and A42/40 with CSF A42, A40, and
A42/40 were determined using univariate Spearman
correlation analyses.
Plasma A42, A40, and A42/40 were compared
between AD patients and controls, and between carri-
ers of the APOE 4 allele (≥1 allele) and non-carriers
using Mann-Whitney tests.
The diagnostic accuracy of plasma A40, plasma
A42, and plasma A42/40 was determined in
receiver operating characteristic (ROC) analyses to
calculate areas under the curve (AUCs) with the out-
come AD patients versus controls. ROC analyses
were performed separately for age, APOE 4, plasma
A40, plasma A42, and plasma A42/40, and for
selected combinations of these predictors. For plasma
A42/40 as the main biomarker of interest, the opti-
mal cut-off and associated sensitivity, specificity and
Youden’s index [44], as well as positive predictive
value (PPV) and negative predictive value (NPV)
were calculated. Analyses were performed in SPSS
(Version 18, IBM SPSS, Chicago, Illinois) and R.
Fig. 1. Plasma A42/40 plotted against CSF A42/40 according to
diagnostic group (rho = 0.22; p = 0.037 across total sample).
RESULTS
Sample characteristics
AD patients were statistically significantly older
and were more likely to have at least one APOE 4
allele compared with controls (Table 1). CSF A42,
CSF A42/40, CSF t-tau, and neuropsychological test
results were in line according to diagnostic group
(data not shown).
Associations of plasma Aβ with CSF biomarkers
In the total sample, plasma A40 was significantly
positively correlated with plasma A42 (Spear-
man’s rho 0.46; p < 0.001). Plasma A42 and plasma
A42/40 were each significantly, albeit weakly, pos-
itively correlated with CSF A40, A42; plasma
A42/40 was additionally positively associated with
CSF A42/40 (Table 2, Fig. 1). Plasma A40 was
not significantly correlated with CSF A40, A42,
or A42/40. When stratified by case-control status,
in controls, plasma A42 and A42/40 were signifi-
cantly correlated with CSF A42, whereas none of the
remaining correlations were statistically significant
(Table 2). In AD patients, plasma A40 was signif-
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Table 3
Plasma A concentration in controls and AD patients
Controls AD Mann-Whitney
Min Max Median Min Max Median p
(interquartile range) (interquartile range)
Plasma A40 (pg/mL) 129 415 237 (212 – 264) 109 376 237 (216 – 267) 0.809
Plasma A42 (pg/mL) 5.8 88.2 19.9 (13.2 – 26.4) 4.8 53.3 17.4 (12.1 – 27.1) 0.404
Plasma A42/40 0.03 0.33 0.08 (0.06 – 0.10) 0.02 0.21 0.07 (0.05 – 0.08) 0.173
n = 93 to 97.
icantly inversely correlated with CSF A42/40, but
none of the remaining correlations were statistically
significant. A40 and A42 concentrations were over-
all around 30-fold and 26-fold higher in CSF than in
plasma respectively (CSF A40, median 6,727 pg/mL
in controls and 7,345 pg/mL in AD patients; CSF
A42, median 677 pg/mL in controls and 310 pg/mL
in AD patients; plasma A40, median 237 pg/mL in
controls and 237 pg/mL in AD patients; plasma A42,
median 20 pg/mL in controls and 17 pg/mL in AD
patients).
Plasma Aβ in AD patients and controls
Plasma A40, plasma A42, and plasma A42/40
were not significantly different between AD patients
and controls (Table 3; Supplementary Figure 1).
In ROC analyses, the area under the curve (AUC)
was 0.51 (95% CI 0.40, 0.63; p = 0.809) for plasma
A40, 0.55 (95% CI 0.43, 0.67; p = 0.404) for plasma
A42, and 0.58 (95% CI 0.46, 0.70; p = 0.173) for
plasma A42/40, indicating that the ability to dis-
criminate between AD patients and controls based
solely on these plasma markers is poor. In compari-
son, the AUCs based on age only or based on APOE
4 only were 0.70 (95% CI 0.59, 0.80; p = 0.001)
and 0.73 (95% CI 0.62, 0.83; p < 0.001) respectively.
When plasma A42/40 as the main biomarker of inter-
est was added to these models, the AUCs did not
change (age and A42/40, AUC, 0.70; 95% CI 0.59,
0.80; p = 0.001; p for difference 0.999; APOE 4 and
A42/40, AUC, 0.76; 95% CI 0.65, 0.87; p < 0.001;
p for difference 0.429). The AUC for a model that
included age and APOE 4 was 0.79 (95% CI 0.69,
0.89; p < 0.001). When plasma A42/40 was added to
this model, the AUC was 0.80 (95% CI 0.70, 0.91;
p < 0.001;p for difference 0.879 see Fig. 2 for selected
biomarker combinations). Taken together, these data
show that plasma A42/40 did not contribute to the
ability to discriminate between AD patients and con-
trols.
Based on the ROC analysis, we determined a cut-
point of 0.076 for a plasma A42/40 concentration
Fig. 2. ROC curves for plasma A42/40 alone, plasma A42/40
with age, and plasma A42/40 with age and APOE 4, in n = 81
patients with complete data. Outcome is “AD” with reference “con-
trols”. To create a ROC curve above the reference line, A42/40
was transformed to “1- A42/40” (blue line).
Fig. 3. Diagnostic accuracy of plasma A42/40 at optimal cut-point
(total n = 93).
with a maximum in both sensitivity and specificity.
However, at this cut-point, plasma A42/40 had low
sensitivity (61.2%) and specificity (63.6%; Youden’s
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index 0.25) and correctly identified 28 of the 44 AD
patients and 30 of the 49 controls. Sixteen AD patients
were misclassified as controls (false negatives) and 19
controls were misclassified as AD cases (false posi-
tives). Plasma A42/40 at this cut-point had a positive
predictive value (PPV) of 59.6% and a negative pre-
dictive value (NPV) of 65.2%. We applied further
experimental cut-points to plasma A42/40 in post-
hoc analyses to reduce the number of false positives,
but all resulted in low diagnostic accuracy (Supple-
mentary Table 1).
Plasma Aβ in non-carriers and carriers of APOE
4
Across the full study sample, plasma A40 (median
238.1 pg/mL versus 228.9 pg/mL; p = 0.466), plasma
A42 (median 21.3 pg/mL versus 16.7 pg/mL;
p = 0.251), and plasma A42/40 (median 0.08 versus
0.07; p = 0.212) were each not statistically different
in non-carriers and in carriers of the APOE 4 allele,
respectively.
DISCUSSION
Blood-based biomarkers of AD have the poten-
tial to revolutionize AD diagnostic procedures. Here,
in a unique case-control study with exceptionally
detailed assessments that included a neuropsycho-
logical examination, CSF biomarker analysis and
brain imaging as gold standards in AD diagnosis, we
found that plasma A was not able to distinguish AD
patients well from biomarker-healthy, non-diseased
controls. Sensitivity and specificity based on plasma
A42/40 levels alone were low and not indicative of
a diagnostic test with scope for clinical application.
Only 64% of AD patients were correctly detected
based on plasma A42/40.
Plasma A42/40 was only weakly but significantly
correlated with CSF A42/40. This finding is in agree-
ment with several previous investigations [27, 30, 45]
though the strength of this correlation was markedly
smaller in our sample. CSF A itself comes with
measurement difficulties [12, 41], but based on its
established function as a gold-standard in AD diag-
nosis [7], combined with the fact that CSF A was
measured using the Mesoscale System (MSD) [41],
our finding suggests that plasma A reflected brain
A burden only to some limited extent. In contrast
to several previous studies comparing AD patients
and controls [22, 30], we did not find evidence of
reduced plasma A in AD patients. Several reasons
may underlie this null result. Firstly, plasma A may
in fact be unrelated to AD status. Secondly, due to
the ‘noise’ associated with peripheral production and
clearance of A [46], effect sizes may have been too
small to detect differences in plasma A between
AD cases and controls. Thirdly, measurement error
from varying time lapse before freezing, from varying
storage time of plasma samples, uncontrolled fasting
status and time of day, and/or plasma A analysis
itself may have affected results. To our knowledge,
we provide the first application of a novel, high-
throughput technique for plasma A analysis [43]
to a research study that was run independently of the
manufacturer. The assay had previously been used
in four studies [28, 45, 47, 48] of which one [47]
used a subsample of an earlier investigation [45]. In
sum, the studies found correlations of plasma A42/40
with CSF A42/40 [45], as well as associations of low
plasma A with presence of [28, 45, 47, 48] and an
increased 3-year accumulation of A burden on PET
[28]. Further, a lower plasma A42/40 was reported
in patients with mild cognitive impairment (MCI)
compared with cognitively normal individuals; addi-
tionally MCI patients with lower plasma A42/40
were at increased risk of 2-year conversion to AD
[45]. In two of the four studies sensitivity, specificity
and AUC of plasma A42/40 for A-positive PET
were more promising [28, 47] compared with our
own analysis comparing AD patients with controls.
Yet, in one of these studies, when the full cohort was
analyzed rather than a subsample, plasma A42/40
performed poorly in discriminating MCI from cog-
nitively normal individuals [47], mirroring our own
results. A cross-sectional analysis of people with sub-
jective cognitive decline, too, found low AUC and low
specificity of the compound alone for A-positive
PET [48]. The final, prospective study on conversion
from MCI to AD only reported a fully adjusted model
that included plasma A as well as age, APOE, and
education [45] so that the added benefit of plasma A
is difficult to evaluate.
The discrepancy of our results from many of the
manufacturer-funded results remains unclear. AD
diagnosis in our study was based on neuropsy-
chological test scores, CSF biomarker analysis and
brain imaging results, and so we are confident that
we have been successful in selecting neurobiolog-
ically diseased AD patients and neurobiologically
healthy controls. That, combined with recent reports
of acceptable diagnostic performance of plasma A
when measured using different high-throughput tech-
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niques [8, 30], leads us to suggest that the assay
may have failed to produce accurate plasma A data.
Technical issues in our study were also indicated by
the fact that plasma A relative to CSF A was far
lower than the expected 10-fold difference [22] our
>20-fold difference mirrored that of another investi-
gation which also found no association of plasma A
with cognitive status [36].
Ametabolism is strongly influenced by theAPOE
protein. APOE is involved in cholesterol transport
in the brain as well as in A production and clear-
ance, and binds to A in CSF [49]. The APOE gene
occurs in three polymorphisms (2; 3; 4) of which
the APOE 4 allele is a strong predictor of late-
onset AD [49]. Carriers of APOE 4 have greater
brain A burden imaged on PET [50, 51] and lower
CSF A compared with non-carriers [51–53]. Several
population-based cohort studies also point to lower
plasma A in carriers [8, 54], but we and others that
have used the same assay [48] found no such evi-
dence. Effect sizes speak against low statistical power
as the root cause, corroborating plasma A—at least
when measured using the present assay—as a periph-
eral biomarker with little scope for capturing AD-type
neuropathological burden.
Detailed characterization of participants using
genetic, CSF biomarker, and brain imaging data is
a strength of our study, but some limitations must
be considered. Due to small sample size, our analy-
ses were underpowered to detect more subtle group
differences in plasma A. For instance, we only
had a two-tailed power of around 30% to detect a
small group difference. Nonetheless, the anticipated
large effect had been reasonable given that we had
selected distinct groups of neurobiologically con-
firmed AD patients and biomarker-healthy controls.
A large group difference is also a prerequisite for
implementation of a diagnostic test in clinical set-
tings, which is at the core of plasma A research.
Time interval between plasma collection and freez-
ing, fasting status, and time of day had not been fully
standardized and this may have contributed to mea-
surement error. However, recent evidence suggests
that plasma A concentration is relatively immune
to these factors [55, 56]. Plasma samples had been
stored for between 7 months and 4 years prior to
extraction from the biobank for A analysis. Though
we are not aware of studies that have assessed an
influence of storage time on plasma A, we have
no reason to believe it may be less stable compared
with A in frozen CSF for which we have previously
demonstrated long-term stability [41]. Finally, we did
not consider AD staging and included both early-
onset and late-onset AD in our sample (6 AD patients
were <65 years old). All of these factors may have
played a role in generating a large range of plasma
A measurements thus may have contributed to our
null findings. At the same time, with exception of
storage time, they are all part of a real-world setting
which any diagnostic test for AD must be able to
withstand for implementation in the clinic.
In a recent analysis of a mostly cognitively
unimpaired older cohort, baseline plasma A
measured with immunoprecipitation and liquid
chromatography-mass spectrometry assay predicted
conversion from amyloid-negative to amyloid-
positive PET during a 4-year follow-up. Results
indicated that implementing the plasma A test in
clinical practice would reduce PET scans by 62%
[8]. Further studies in this direction are needed in
spite of the present null findings to fully determine
the diagnostic value of plasma A and for head-to-
head comparison with other biomarkers of brain A
burden. For instance, plasma t-tau [57] and plasma
neurofilament light (NFL) [58] have recently been
reported as predictive of AD in three independent
cohorts. Serum NFL has also been shown to be ele-
vated in patients with familial AD [59] and to predict
their rate of cognitive decline [60]. A substantial
proportion of patients with MCI or dementia with
potential AD etiology appears to be misdiagnosed
once followed up with amyloid PET [17], and plasma
biomarkers could be evaluated as follow-up diagnos-
tic tools. For A in particular, different methods for
measuring plasma concentration of the protein should
be compared with one another and with a recently
developed structure-based approach that measures
misfolded A [61]. The goal should be to standard-
ize analysis methods across labs. Here, we did not
create CSF/plasma A ratios, because AD diagno-
sis was based in part on CSF A so that such ratios
would have led to circular arguments, but future stud-
ies could explore their usefulness (e.g., [36]) as well
as ratios combining several plasma biomarkers (e.g.,
[62]).
Any biomarker of AD needs to offer scope
for large-scale application. Here, we used a
recently established, commercially available, high-
throughput technique and found that plasma A
correlated weakly with CSF A and was unable
to distinguish between AD patients and biomarker-
healthy, non-diseased controls. Plasma A at the
cut-point with maximum sensitivity and specificity
identified 38% of our sample incorrectly as false pos-
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itive or false negative. We thus deem its performance
inacceptable. Diagnostic confidence for clinical AD
diagnosis can be considered exceptionally high in our
study because AD diagnosis was based on a com-
bination of detailed diagnostic procedures that are
not routinely applied in clinical practice outside of
specialized memory clinics. Plasma A measured
with the present assay can therefore be expected to be
even less adequate in more diverse, ‘real-world’ sam-
ples that include ‘gray zones’ and prodromal stages
of AD. Nonetheless, plasma A may well be a use-
ful biomarker of age-related cognitive impairment
in population-based epidemiological research studies
aimed at risk stratification and elucidation of patho-
physiological mechanisms underlying impairment.
The utility of the blood A assay presented here is
yet to be determined in that context.
Overall, we conclude that as the evidence cur-
rently stands, the plasma A concentration assay may
have limited ability to distinguish AD cases from
biomarker-healthy, non-diseased controls. Its evalua-
tion in larger samples and, potentially, a shift of focus
toward other blood-based biomarkers and/or efforts
for technological advancement of plasma A mea-
surement, which has recently gained momentum [30],
are warranted.
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